Don S. Dizon
Advanced in Angiosarcoma

Dr. Don S. Dizon

Oncology
Rhode Island Hospital
593 Eddy St, Apc 138, 
Providence, RI 
Advanced in Angiosarcoma
Rhode Island Hospital
593 Eddy St, Apc 138, 
Providence, RI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Don Dizon is an Oncologist in Providence, Rhode Island. Dr. Dizon is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Endometrial Cancer, Breast Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 216 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Angiosarcoma.

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Tufts Medical Center
Rhode Island Hospital
The Miriam Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

RHODE ISLAND HOSPITAL
593 Eddy St, Apc 138, Providence, RI 02903
Other Locations
PRATT MEDICAL GROUP INC
800 Washigton St, Boston, MA 02111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Nivolumab, Rucaparib
Study Phase: Phase 2
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
BrUOG 355: A Pilot Feasibility Study Incorporating Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
BrUOG 355: A Pilot Feasibility Study Incorporating Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
Enrollment Status: Terminated
Publish Date: April 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Cisplatin
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)
BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)
Enrollment Status: Terminated
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drug: Talazoparib Oral Capsule
Study Phase: Phase 1
Step Into Support for Endurance and Strength (SISTERS)
Step Into Support for Endurance and Strength (SISTERS)
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Enrollment Status: Withdrawn
Publish Date: December 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

215 Total Publications

Using Quality Improvement and Implementation Science to Identify Strategies That Foster Electronic Patient-Reported Outcome Submissions.
Using Quality Improvement and Implementation Science to Identify Strategies That Foster Electronic Patient-Reported Outcome Submissions.
Journal: Journal for healthcare quality : official publication of the National Association for Healthcare Quality
Published: July 24, 2025
Similar Doctors
Elite in Angiosarcoma
Dr. Katherine Thornton
Oncology
Elite in Angiosarcoma
Dr. Katherine Thornton
Oncology
450 Brookline Ave, 
Boston, MA 
 (39.5 miles away)
617-632-5204
Languages Spoken:
English

Katherine Thornton is an Oncologist in Boston, Massachusetts. Dr. Thornton is rated as an Elite provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Angiosarcoma, Synovial Sarcoma, and Bone Tumor.

Harold J. Burstein
Distinguished in Angiosarcoma
Dr. Harold J. Burstein
Oncology
Distinguished in Angiosarcoma
Dr. Harold J. Burstein
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (39.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Harold Burstein is an Oncologist in Boston, Massachusetts. Dr. Burstein is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Burstein is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Steven E. Come
Oncology
Distinguished in Angiosarcoma
Dr. Steven E. Come
Oncology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (39.7 miles away)
617-754-8612
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Come is an Oncologist in Boston, Massachusetts. Dr. Come is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Come is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dizon's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile